These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 30741558

  • 21. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Elkon JM, Millett RL, Millado KF, Lin J.
    Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266
    [Abstract] [Full Text] [Related]

  • 22. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [Abstract] [Full Text] [Related]

  • 23. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F.
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C, Jimeno A, Kessler ER.
    Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
    [Abstract] [Full Text] [Related]

  • 26. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
    Yang H, Pang L, Hu X, Wang W, Xu B, Zhang X, Liu L.
    J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
    [Abstract] [Full Text] [Related]

  • 27. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S, Carlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, Aschelter AM, Felici A, Valeriani M, Cognetti F, Marchetti P.
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Abiraterone in castration resistant prostate cancer.].
    Juárez Soto A, Caballero Cobos R, Campanario Pérez R, Saiz Marenco R, Herrera Torres M, Gamaza Martínez R, Amores Bermúdez J.
    Arch Esp Urol; 2018 Sep; 71(8):651-663. PubMed ID: 30319125
    [Abstract] [Full Text] [Related]

  • 30. Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high- and middle-income Asian countries.
    Lim J, Onozawa M, Saad M, Ong TA, A-CaP (Asian Prostate Cancer) Study, J-CaP (Japan Prostate Cancer Study Group), M-CaP (Malaysia Prostate Cancer Study Group), Malek R, Akaza H.
    Cancer Sci; 2021 Jun; 112(6):2071-2080. PubMed ID: 33738901
    [Abstract] [Full Text] [Related]

  • 31. The evolving options in metastatic castration-sensitive prostate cancer.
    Hamilou Z.
    Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
    [Abstract] [Full Text] [Related]

  • 32. Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?
    Belderbos BPS, de Wit R, Lolkema MPJ, Mathijssen RHJ, van Soest RJ.
    Ann Oncol; 2019 Oct 01; 30(10):1591-1600. PubMed ID: 31340031
    [Abstract] [Full Text] [Related]

  • 33. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.
    Lancet Oncol; 2015 Jul 01; 16(7):787-94. PubMed ID: 26028518
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F, Goebell PJ, Wullich B, Sikic D, Kahlmeyer A.
    World J Urol; 2020 Mar 01; 38(3):601-611. PubMed ID: 30830274
    [Abstract] [Full Text] [Related]

  • 36. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
    Tan PS, Aguiar P, Haaland B, Lopes G.
    Prostate Cancer Prostatic Dis; 2018 Nov 01; 21(4):516-523. PubMed ID: 29875432
    [Abstract] [Full Text] [Related]

  • 37. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
    Clin Oncol (R Coll Radiol); 2013 Jul 01; 25(7):406-30. PubMed ID: 23587782
    [Abstract] [Full Text] [Related]

  • 38. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI.
    J Clin Oncol; 2018 May 20; 36(15):1521-1539. PubMed ID: 29608397
    [Abstract] [Full Text] [Related]

  • 39. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Jang HS, Koo KC, Cho KS, Chung BH.
    Yonsei Med J; 2016 Sep 20; 57(5):1070-8. PubMed ID: 27401636
    [Abstract] [Full Text] [Related]

  • 40. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
    Grisay G, Lavaud P, Fizazi K.
    Curr Oncol Rep; 2024 May 20; 26(5):488-495. PubMed ID: 38592590
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.